TIM‑3 expression and its association with overall survival in primary osteosarcoma

Pu,Feifei; Chen,Fengxia; Zhang,Zhicai; Qing,Xiangcheng; Lin,Hui; Zhao,Lei; Xia,Ping; Shao,Zengwu

doi:10.3892/ol.2019.10855

TIM‑3 expression and its association with overall survival in primary osteosarcoma

Authors:
- Feifei Pu
- Fengxia Chen
- Zhicai Zhang
- Xiangcheng Qing
- Hui Lin
- Lei Zhao
- Ping Xia
- Zengwu Shao
View Affiliations

Affiliations: Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Orthopedics, Wuhan Integrated Traditional Chinese Medicine and Western Medicine Hospital, Wuhan, Hubei 430071, P.R. China
Published online on: September 12, 2019 https://doi.org/10.3892/ol.2019.10855
Pages: 5294-5300
Copyright: © Pu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

T‑cell immunoglobulin and mucin domain‑containing-3 (TIM‑3) performs a critical function in immune tolerance by suppressing the activation and proliferation of T cells. TIM‑3 serves an important role in tumor progression in a number of carcinomas, including non‑small cell lung cancer, hepatitis B virus‑associated hepatocellular carcinoma, Langerhans cell sarcoma, head and neck cancer and follicular B cell non‑Hodgkin lymphoma. The aim of the present study was to evaluate the possible association of TIM‑3 with the prognosis of osteosarcoma. TIM‑3 expression was assessed by immunohistochemical analysis in osteosarcoma tissues. The association between TIM‑3 expression and prognosis was examined. To assess the association between TIM‑3 expression levels and clinicopathological features, a Fisher's exact test was used. TIM‑3 overexpression was indicated to be associated with surgical treatment and survival. Kaplan‑Meier analysis indicated that TIM‑3 is an independent predictor of overall survival, and its overexpression was indicated to be associated with poor prognosis in patients with osteosarcoma. Additionally, reverse transcription‑quantitative polymerase chain reaction and western blot analysis were carried out to evaluate TIM‑3 expression levels in fresh tumor tissue samples, adjacent‑tissue samples, osteosarcoma cell lines, and in an osteoblastic cell line. TIM‑3 was indicated to be overexpressed in fresh osteosarcoma tissue samples and in osteosarcoma cell lines. In conclusion, TIM‑3 overexpression is associated with poor survival among patients with osteosarcoma and may be a possible therapeutic target in these types of tumors.

View Figures

View References

1	Biermann JS, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Butrynski JE, Cheong D, Chow W, Curry WT, Frassica DA, et al: Bone cancer. J Natl Compr Canc Netw. 11:688–723. 2013. View Article : Google Scholar : PubMed/NCBI
2	Lindsey BA, Markel JE and Kleinerman ES: Osteosarcoma overview. Rheumatol Ther. 4:25–43. 2017. View Article : Google Scholar : PubMed/NCBI
3	He JP, Hao Y, Wang XL, Yang XJ, Shao JF, Guo FJ and Feng JX: Review of the molecular pathogenesis of osteosarcoma. Asian Pac J Cancer Prev. 15:5967–5976. 2014. View Article : Google Scholar : PubMed/NCBI
4	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
5	Liu S, Geng P, Cai X and Wang J: Comprehensive evaluation of the cytotoxic T-lymphocyte antigen-4 gene polymorphisms in risk of bone sarcoma. Genet Test Mol Biomarkers. 18:574–579. 2014. View Article : Google Scholar : PubMed/NCBI
6	Fan Y, Zhang C, Jin S, Gao Z, Cao J, Wang A, Li D, Wang Q, Sun X and Bai D: Progress of immune checkpoint therapy in the clinic (Review). Oncol Rep. 41:3–14. 2019.PubMed/NCBI
7	Wang SD, Li HY, Li BH, Xie T, Zhu T, Sun LL, Ren HY and Ye ZM: The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma. Int Immunopharmacol. 38:81–89. 2016. View Article : Google Scholar : PubMed/NCBI
8	Ledford H, Else H and Warren M: Cancer immunologists scoop medicine Nobel prize. Nature. 562:20–21. 2018. View Article : Google Scholar : PubMed/NCBI
9	Gibney GT, Weiner LM and Atkins MB: Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17:e542–e551. 2016. View Article : Google Scholar : PubMed/NCBI
10	Markwick LJ, Riva A, Ryan JM, Cooksley H, Palma E, Tranah TH, Manakkat Vijay GK, Vergis N, Thursz M, Evans A, et al: Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. Gastroenterology. 148:590–602.e10. 2015. View Article : Google Scholar : PubMed/NCBI
11	Das M, Zhu C and Kuchroo VK: Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 276:97–111. 2017. View Article : Google Scholar : PubMed/NCBI
12	Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ and Anderson AC: TIM3⁺FOXP3⁺ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. 2:e238492013. View Article : Google Scholar : PubMed/NCBI
13	Li Z, Li N, Li F, Zhou Z, Sang J, Chen Y, Han Q, Lv Y and Liu Z: Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma. Medicine (Baltimore). 95:e57492016. View Article : Google Scholar : PubMed/NCBI
14	Present D, Bertoni F, Hudson T and Enneking WF: The correlation between the radiologic staging studies and histopathologic findings in aggressive stage 3 giant cell tumor of bone. Cancer. 57:237–244. 1986. View Article : Google Scholar : PubMed/NCBI
15	Fletcher CDM, Bridge JA, Hogendoorn P and Mertens F: WHO classification of tumours of soft tissue and boneLyon: IARC Press; pp. 239–394. 2013
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Sarsilmaz A, Argin M, Sezak M, Altay C and Erdogan N: Primary osteosarcoma arising from subcutaneous tissue: 5-year follow-up. Clin Imaging. 36:402–405. 2012. View Article : Google Scholar : PubMed/NCBI
18	Mavrogenis AF, Rossi G, Palmerini E, Errani C, Rimondi E, Ruggieri P, Soucacos PN and Papagelopoulos PJ: Palliative treatments for advanced osteosarcoma. J BUON. 17:436–445. 2012.PubMed/NCBI
19	Shang Y, Li Z, Li H, Xia H and Lin Z: TIM-3 expression in human osteosarcoma: Correlation with the expression of epithelial-mesenchymal transition-specific biomarkers. Oncol Lett. 6:490–494. 2013. View Article : Google Scholar : PubMed/NCBI
20	Liu H, Zhi L, Duan N and Su P: Abnormal expression of Tim-3 antigen on peripheral blood T cells is associated with progressive disease in osteosarcoma patients. FEBS Open Bio. 6:807–815. 2016. View Article : Google Scholar : PubMed/NCBI
21	Piao YR, Jin ZH, Yuan KC and Jin XS: Analysis of Tim-3 as a therapeutic target in prostate cancer. Tumour Biol. 35:11409–11414. 2014. View Article : Google Scholar : PubMed/NCBI